Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Summary
This is a phase 2/3 open-label trial to evaluate the long-term safety, tolerability, and efficacy of sibeprenlimab administered subcutaneously (SC) in subjects with IgAN.
Official title: A Phase 2/3, Multicenter, Open-label Trial to Evaluate the Long-term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
600
Start Date
2022-04-05
Completion Date
2028-12-28
Last Updated
2024-12-09
Healthy Volunteers
No
Conditions
Interventions
Sibeprenlimab 400 mg s.c. Q4weeks
Sibeprenlimab 400 mg s.c. q 4 weeks
Locations (1)
For additional information regarding sites, contact 844-687-8522
New York, New York, United States